Follow AGEN's trial news. Pro members can get an alert when Agenus files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 4.5% on an up day: the S&P 500 is up 1.6% and 7 in 10 stocks are higher; health care stocks are up 3.0%; energy and drone stocks fell.
Beats this year
Up 87% in a year while the S&P 500 rose 15%; down 55% over three years.
| The company | Sales up 30% on the year |
| Latest filing | S-3, Sep 11 |
TodayOn an up day.
Wed Nov 4: Society for Immunotherapy of Cancer…Industry event · date confirmed.
After its last 4 reports it closed -1.6% on average, higher 2 of 4 times.
The company says its cash lasts through year-end 2031 (8-K, Jul 13).
No shelf registration or at-the-market program on file in the last three years.
No open-market buys or sales by its officers or directors in their filings of the last year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 4 of 14 chart checks firingWhat the Quality Score means
AGEN is #57 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 57 |
Reports Thu Nov 5, before the open (tomorrow). Confirmed.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 6, 2026 | -1.4% | -3.7% | -11.3% |
| May 11, 2026 | -5.5% | -14.7% | -6.3% |
| Mar 16, 2026 | +0.5% | +6.1% | +19.7% |
Sales grew in four of the last seven years, to $114M in 2025. It lost money in each of the eight years.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: AGEN is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Agenus Inc is a clinical-stage biotechnology company focused on discovering and developing immunotherapies for cancer and infectious diseases. Its primary business is immuno-oncology (I-O), where it advances antibody-based programs designed to activate innate and adaptive immunity, overcome tumor immune evasion, and expand the number of patients who may benefit from immunotherapy. The Company's clinical program includes botensilimab (BOT or AGEN1181), both as a monotherapy and in combination with balstilimab (BAL), alongside a portfolio of other clinical-stage immuno-oncology assets that may be used independently or in combination therapies. The Company operates in the United States, which contributes the majority of its revenue, as well as in other international markets.
“Competition in the pharmaceutical and biotechnology industries is intense.”
AGEN scores 8 today, which Breakaway calls Average. It is #57 of 291 in Biotech by Quality Score, with 4 of 14 chart checks firing. Up 87% in a year while the S&P 500 rose 15%; down 55% over three years. Shares: 47.0% more than a year ago (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
AGEN scores 8 today, which Breakaway calls Average (6 to 10). That is #57 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind AGEN's 8.
Reports Thu Nov 5, before the open, a date the company confirmed. AGEN closed higher after 2 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.